Recombinant activated factor VII in cardiac surgery – first, do no harm
2007

Concerns About Recombinant Activated Factor VII in Cardiac Surgery

publication Evidence: moderate

Author Information

Author(s): Warren Oliver J, Ara W Darzi, Thanos Athanasiou

Primary Institution: Imperial College London

Hypothesis

What are the risks associated with using recombinant activated factor VII in patients undergoing cardiac surgery?

Conclusion

Patients undergoing VAD surgery may be at a higher risk of thromboembolic events when administered rFVIIa.

Supporting Evidence

  • The authors argue that the pro-coagulatory effect of rFVIIa may not function the same way in patients with VAD.
  • Significant controversy exists regarding the role of tissue factor in cardiac surgery patients.
  • Evidence suggests that the risk of thromboembolic events may be underestimated in the literature.

Takeaway

Using a special medicine called rFVIIa in heart surgery might cause serious blood clots, so doctors need to be very careful.

Potential Biases

There is a high risk of publication and selection bias due to the nature of the data sources.

Limitations

The study relies on existing literature, which may have biases and underreporting of adverse events.

Digital Object Identifier (DOI)

10.1186/1749-8090-2-50

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication